Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan

阿尔法 医学 贫血 内科学 艾博汀阿尔法 血液透析 随机对照试验
作者
Tadao Akizawa,Manabu Iwasaki,Yusuke Yamaguchi,Yoshikatsu Majikawa,Michael Reusch
出处
期刊:Journal of The American Society of Nephrology 卷期号:31 (7): 1628-1639 被引量:170
标识
DOI:10.1681/asn.2019060623
摘要

Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved in China for dialysis-dependent CKD anemia.This phase 3, 24-week, double-blind, double-dummy study evaluated roxadustat's noninferiority to darbepoetin alfa for hemodialysis-dependent CKD anemia. We randomly assigned Japanese patients to oral roxadustat three times weekly or to darbepoetin alfa injections once weekly, titrating doses to maintain hemoglobin between 10-12 g/dl. The primary end point was change of average hemoglobin from baseline to weeks 18-24 (∆Hb18-24). Secondary end points were average hemoglobin and proportion of patients with hemoglobin between 10-12 g/dl (maintenance rate) at weeks 18-24, and iron parameters. Safety assessments included treatment-emergent adverse events and adjudicated ophthalmologic findings.We randomly assigned 303 patients to roxadustat (n=151) or darbepoetin alfa (n=152). The difference between roxadustat and darbepoetin alfa in ∆Hb18-24 was -0.02 g/dl (95% confidence interval, -0.18 to 0.15), confirming roxadustat's noninferiority to darbepoetin alfa. Average hemoglobin at weeks 18-24 with roxadustat was 10.99 g/dl (95% confidence interval: 10.88 to 11.10), confirming its efficacy. Among patients with one or more hemoglobin value during weeks 18-24, the maintenance rate was 95.2% with roxadustat and 91.3% with darbepoetin alfa. Serum iron, ferritin, and transferrin saturation remained clinically stable with roxadustat; transferrin and total iron binding capacity increased through week 4 before stabilizing. Common treatment-emergent adverse events were nasopharyngitis, shunt stenosis, diarrhea, contusion, and vomiting. The proportion of patients with new or worsening retinal hemorrhage was 32.4% with roxadustat and 36.6% with darbepoetin alfa. We observed no clinically meaningful changes in retinal thickness groups.Roxadustat maintained hemoglobin within 10-12 g/dl in patients on hemodialysis and was noninferior to darbepoetin alfa. Treatment-emergent adverse events were consistent with previous reports.A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients with Anemia, NCT02952092 (ClinicalTrials.gov).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
赵胜男完成签到 ,获得积分10
1秒前
2秒前
共享精神应助坚强的樱采纳,获得10
2秒前
3秒前
千陽完成签到,获得积分10
3秒前
bluesiryao完成签到,获得积分10
3秒前
Miracle完成签到,获得积分10
3秒前
托丽莲睡拿完成签到,获得积分10
3秒前
3秒前
3秒前
DAYTOY发布了新的文献求助50
4秒前
杀出个黎明举报求助违规成功
4秒前
whatever举报求助违规成功
4秒前
iNk举报求助违规成功
4秒前
4秒前
linxue完成签到,获得积分10
4秒前
蛋蛋1完成签到,获得积分10
5秒前
5秒前
6秒前
ss发布了新的文献求助10
6秒前
SHJ完成签到,获得积分20
6秒前
海棠听风发布了新的文献求助10
7秒前
23发布了新的文献求助10
7秒前
xde145完成签到,获得积分10
7秒前
8秒前
shime完成签到,获得积分10
8秒前
费城青年发布了新的文献求助10
8秒前
8秒前
9秒前
SHDeathlock给SHDeathlock的求助进行了留言
10秒前
10秒前
10秒前
马静雨发布了新的文献求助50
11秒前
拼搏起眸发布了新的文献求助10
12秒前
二二二发布了新的文献求助10
12秒前
科目三应助柴火烧叽采纳,获得10
12秒前
啊实打实的卡完成签到,获得积分10
12秒前
orixero应助大智若愚啊采纳,获得10
12秒前
Z.完成签到 ,获得积分10
12秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Social media impact on athlete mental health: #RealityCheck 1020
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527849
求助须知:如何正确求助?哪些是违规求助? 3107938
关于积分的说明 9287239
捐赠科研通 2805706
什么是DOI,文献DOI怎么找? 1540033
邀请新用户注册赠送积分活动 716893
科研通“疑难数据库(出版商)”最低求助积分说明 709794